

## **Draft Guidance on Dextromethorphan Hydrobromide; Quinidine Sulfate**

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active ingredient:** Dextromethorphan Hydrobromide; Quinidine Sulfate

**Form/Route:** Capsule/Oral

**Recommended studies:** 2 studies

1. Type of study: Fasting

Design: Single-dose, two-way crossover in-vivo

Strength: 20 mg; 10 mg

Subjects: Healthy males and females, general population.

Additional comments: Females should not be pregnant or lactating, and if applicable, should practice abstinence or contraception during the study. Subjects with any of the following should be excluded:

- History of quinidine, quinine or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions.
- Known hypersensitivity to dextromethorphan, current use of an MAOI or within 14 days of stopping an MAOI, prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, or heart failure, complete atrioventricular (AV) block without implanted pacemaker, or patients at high risk of complete AV block.
- QTc interval of >480 msec by ECG in baseline 12-lead ECG.

---

2. Type of study: Fed

Design: Single-dose, two-way crossover in-vivo

Strength: 20 mg; 10 mg

Subjects: Healthy males and females, general population.

Additional comments: See above "Additional comments"

---

**Analytes to measure (in appropriate biological fluid):** Dextromethorphan and Quinidine in plasma

**Bioequivalence based on (90% CI):** Dextromethorphan and Quinidine

**Waiver request of in-vivo testing:** Not Applicable

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.